Go Deep
Suven Life Sciences Limited
Suven Life Sciences Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 16,905 | -18.0 | 12.79 | 0.03 | 267.65 |
Suven Life Sciences Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 35,658,000.0 | 15,201,000.0 | 28,087,000.0 | 9,192,000.0 |
| Net Profit | -1,276,103,000.0 | -455,955,000.0 | -1,019,218,000.0 | -773,099,000.0 |
| EPS | -4.8 | -2.0 | -4.5 | -3.5 |
Suven Life Sciences Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 71,147,000.0 | 66,558,000.0 | 116,930,000.0 | 135,392,000.0 | — |
| Net Profit | -2,763,441,000.0 | -1,607,450,000.0 | -1,050,762,000.0 | -1,182,678,000.0 | — |
| EPS | -12.1 | -7.4 | -4.8 | -6.6 | — |
Suven Life Sciences Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 6,242,140,000.0 | 1,351,833,000.0 | 2,849,027,000.0 | 3,889,106,000.0 | — |
| Total Liabilities | 328,142,000.0 | 251,965,000.0 | 148,621,000.0 | 135,912,000.0 | — |
| Total Equity | 5,913,998,000.0 | 1,099,868,000.0 | 2,700,406,000.0 | 3,753,194,000.0 | — |
Owes vs Owns
Suven Life Sciences Limited owed ₹0.05 for every ₹1 it owned in Mar 2026, up from ₹0.03 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.05× | 0.19× | 0.05× | 0.03× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Suven Life Sciences Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 30.3%Fixed assets (tangible) 12.3%Other assets 57.1%
How it's funded — Mar 2026
Short-term debt 0.7%Long-term debt 1.9%Payables 0.8%Other liabilities 1.8%Shareholders' equity 94.7%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 188.9 | 37.3 | 90.9 | 83.4 |
| Receivables | 1.5 | 1.3 | 1.3 | 0.8 |
| Inventory | 0.1 | 0.2 | 0.7 | 0.0 |
| Fixed assets (tangible) | 76.5 | 59.5 | 28.0 | 37.1 |
| Intangible assets | 0.1 | 0.2 | 0.2 | 0.2 |
| Long-term investments | 0.9 | 0.0 | 0.0 | 100.0 |
| Other assets | 356.2 | 36.6 | 163.8 | 167.4 |
| Liabilities & equity | ||||
| Short-term debt | 4.5 | 0.0 | 0.0 | 0.0 |
| Long-term debt | 12.1 | 0.0 | 0.0 | 0.0 |
| Payables | 4.8 | 5.2 | 2.1 | 1.7 |
| Other liabilities | 11.3 | 20.0 | 12.8 | 11.9 |
| Shareholders' equity | 591.4 | 110.0 | 270.0 | 375.3 |
| Net tangible assets | 591.3 | 109.8 | 269.8 | 375.1 |
Suven Life Sciences Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | -3,014,143,000.0 | -1,541,046,000.0 | -826,186,000.0 | -1,159,811,000.0 | — |
| Investing Activities | -4,621,138,000.0 | 1,549,541,000.0 | 615,859,000.0 | -2,478,125,000.0 | — |
| Financing Activities | 7,567,816,000.0 | -7,563,000.0 | -10,540,000.0 | 3,955,391,000.0 | — |